Literature DB >> 18162388

The Medical Research Council chronic dyspnea score predicts the survival of patients with idiopathic pulmonary fibrosis.

Effrosyni D Manali1, Georgios T Stathopoulos, Androniki Kollintza, Ioannis Kalomenidis, Joseph Milic Emili, Christina Sotiropoulou, Zoe Daniil, Charis Roussos, Spyros A Papiris.   

Abstract

BACKGROUND: The Medical Research Council (MRC) chronic dyspnea scale (6-point) is used in different clinical conditions to grade breathlessness on daily activities. We have previously shown that in patients with histologically documented usual interstitial pneumonia/idiopathic pulmonary fibrosis (UIP/IPF), the MRC dyspnea scale is useful in estimating disease severity. The aim of this study was to further investigate the usefulness of the MRC scale in IPF as a marker of survival.
METHODS: The records of 25 patients with histologically documented UIP/IPF were retrospectively reviewed. Clinical parameters, pulmonary function tests, and arterial blood gases at the time of diagnosis, as well as survival time were retrieved and recorded for each patient. The impact of the different variables determined at diagnosis on survival was examined using the Kaplan-Meier and uni- and multi-variate Cox-regression analyses.
RESULTS: Among the baseline clinical and physiologic parameters determined at the time of IPF diagnosis, the MRC score, the Tiffeneau index, and the total lung capacity were the only significant and independent predictors of survival. In specific, a high MRC score, a high Tiffeneau index, and a low total lung capacity at presentation were associated with shorter survival.
CONCLUSION: In accordance with the previous work, our results indicate that the Tiffeneau index and total lung capacity (TLC) are the important determinants of survival in patients with IPF. In addition, we show that the simple MRC chronic dyspnea score estimated at the time of diagnosis is equally predictive of survival and may aid clinicians in assessing the prognosis of new cases of IPF.

Entities:  

Mesh:

Year:  2007        PMID: 18162388     DOI: 10.1016/j.rmed.2007.11.008

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  14 in total

1.  Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form.

Authors:  Monique Hinchcliff; Jennifer L Beaumont; Krishna Thavarajah; John Varga; Anh Chung; Sofia Podlusky; Mary Carns; Rowland W Chang; David Cella
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

2.  Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations.

Authors:  Helen E Jo; Sharan Randhawa; Tamera J Corte; Yuben Moodley
Journal:  Drugs Aging       Date:  2016-05       Impact factor: 3.923

3.  Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity.

Authors:  Hana Serajeddini; Paola Rogliani; Marco Mura
Journal:  Lung       Date:  2018-08-27       Impact factor: 2.584

4.  A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.

Authors:  C Rinciog; M Watkins; S Chang; T M Maher; C LeReun; D Esser; A Diamantopoulos
Journal:  Pharmacoeconomics       Date:  2017-04       Impact factor: 4.981

5.  MRC chronic Dyspnea Scale: Relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study.

Authors:  Effrosyni D Manali; Panagiotis Lyberopoulos; Christina Triantafillidou; Likourgos F Kolilekas; Christina Sotiropoulou; Joseph Milic-Emili; Charis Roussos; Spyros A Papiris
Journal:  BMC Pulm Med       Date:  2010-05-28       Impact factor: 3.317

6.  Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.

Authors:  Brett Ley; Williamson Z Bradford; Eric Vittinghoff; Derek Weycker; Roland M du Bois; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

7.  Gender influences Health-Related Quality of Life in IPF.

Authors:  MeiLan K Han; Jeffrey Swigris; Lyrica Liu; Brian Bartholmai; Susan Murray; Nicholas Giardino; Bruce Thompson; Margaret Frederick; Daner Li; Marvin Schwarz; Andrew Limper; Kevin Flaherty; Fernando J Martinez
Journal:  Respir Med       Date:  2009-12-24       Impact factor: 3.415

8.  Medical Research Council dyspnea scale does not relate to fibroblast foci profusion in IPF.

Authors:  Christina Triantafillidou; Effrosyni D Manali; Christina Magkou; Christina Sotiropoulou; Likurgos F Kolilekas; Konstantinos Kagouridis; Dimitra Rontogianni; Spyros A Papiris
Journal:  Diagn Pathol       Date:  2011-04-05       Impact factor: 2.644

Review 9.  Opioids: an unexplored option for treatment of dyspnea in IPF.

Authors:  Charlotte Kohberg; Charlotte Uggerhøj Andersen; Elisabeth Bendstrup
Journal:  Eur Clin Respir J       Date:  2016-03-10

10.  The Role of Cardiopulmonary Exercise Test in IPF Prognosis.

Authors:  Christina Triantafillidou; Effrosyni Manali; Panagiotis Lyberopoulos; Likourgos Kolilekas; Konstantinos Kagouridis; Sotirios Gyftopoulos; Konstantinos Vougas; Anastasia Kotanidou; Manos Alchanatis; Anna Karakatsani; Spyros A Papiris
Journal:  Pulm Med       Date:  2013-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.